Tuesday, February 02, 2021 4:09:13 PM
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235686
This Supplement No. 1 to Prospectus Supplement supplements and amends the Prospectus Supplement dated November 12, 2020 (the “Prospectus Supplement”) filed by us. This Supplement No. 1 to Prospectus Supplement should be read in conjunction with the Prospectus Supplement and the Prospectus dated April 9, 2020.
We previously entered into a purchase agreement, dated as of November 12, 2020 (“Purchase Agreement”), with Lincoln Park Capital Fund, LLC, or Lincoln Park, related to the issuance and sale of up to $22,000,000 of shares of our common stock that we may sell to Lincoln Park from time to time pursuant to the Purchase Agreement, as well as 126,699 shares of our common stock (taking into account the one-for-six reverse stock split completed January 29, 2021) issued to Lincoln Park as commitment shares under the Purchase Agreement, and up to an additional 50,680 shares of our common stock (taking into account the one-for-six reverse stock split completed January 29, 2021) that may be issued to Lincoln Park as commitment shares pro-rata when and if Lincoln Park purchased the $22,000,000 aggregate commitment.
We filed the Prospectus Supplement to a base prospectus dated April 9, 2020 (the “Base Prospectus”), to register the issuance and sale of up to $22,000,000 of shares of our common stock that we may sell to Lincoln Park pursuant to the Purchase Agreement, the 126,699 shares of our common stock (taking into account the one-for-six reverse stock split completed January 29, 2021) issued to Lincoln Park as commitment shares under the Purchase Agreement, and up to an additional 50,680 shares of our common stock (taking into account the one-for-six reverse stock split completed January 29, 2021) that may be issued to Lincoln Park as commitment shares pro-rata when and if Lincoln Park purchased (at our discretion) the $22,000,000 aggregate commitment.
We terminated the Purchase Agreement on February 2, 2021. We sold a total of 638,203 shares of common stock (taking into account the one-for-six reverse stock split completed January 29, 2021) pursuant to the Prospectus Supplement for total proceeds of $2,742,499.67 and issued a total of 133,017 commitment shares (taking into account the one-for-six reverse stock split completed January 29, 2021) pursuant to the Prospectus Supplement. The purpose of this Supplement No. 1 to Prospectus Supplement is to terminate the offering under the Prospectus Supplement and the Base Prospectus, effective on the termination date.
The date of this prospectus supplement no. 1 is February 2, 2021
Recent MBRX News
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference • PR Newswire (US) • 03/28/2024 02:45:00 PM
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity • PR Newswire (US) • 03/27/2024 01:25:00 PM
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML • PR Newswire (US) • 03/27/2024 01:05:00 PM
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial • PR Newswire (US) • 03/25/2024 11:30:00 AM
- Moleculin Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/22/2024 08:05:00 PM
- Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 03/20/2024 11:30:00 AM
- JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News • IH Market News • 03/20/2024 11:15:48 AM
- Moleculin Announces Reverse Stock Split • PR Newswire (US) • 03/19/2024 08:30:00 PM
- Moleculin to Present at the 36th Annual ROTH Conference • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 02:30:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:19:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:15:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:36:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:33:22 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:17 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 10:05:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 01:50:30 PM
- Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 • PR Newswire (US) • 01/24/2024 01:50:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/16/2024 10:00:41 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/05/2024 10:15:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:14:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 12:31:57 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM